Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with l
Bayer's venture capital unit has co-led a $175 million investment in Affini-T that will be used to take its T cell receptor (TCR) therapies for cancer cells with mutations like KRAs and p53